Histogen is a regenerative medicine company focused on developing patented, innovative technologies for aesthetic and therapeutic markets that replace and regenerate tissues in the body. The Company currently has three product candidates in clinical development intended to address what Histogen believes to be underserved, multi-billion dollar global markets: a treatment for hair loss, a dermal filler and a treatment for joint cartilage repair.

History

Histogen, Inc., a Delaware Corporation, was founded in 2007. The Company is focused on developing innovative products based upon Histogen’s unique technology that utilizes the proteins and growth factors produced by cells grown under simulated embryonic conditions. The Company is headquartered in San Diego, California.

Histogen founder Dr. Gail Naughton is a highly respected scientist with extensive experience in the field of tissue engineering and regenerative medicine. Dr. Naughton discovered the potential of proteins and growth factors produced by hypoxia-induced multipotent cells for therapeutic and biomedical applications, and developed Histogen’s unique technology process to create products based on these proteins. The technology is protected by patent families filed in the US and across key geographies.

Our Mission

To redefine regenerative medicine by developing high value therapeutic and aesthetic products that stimulate the body’s own stem cells to regenerate tissues, without the use of embryonic stem cells or animal components.

Histogen’s executive management team has decades of experience in bringing cell-based regenerative products from concept to market. In addition, the Company’s Board of Directors and scientific advisors are leaders in the fields of regenerative medicine and global marketing and business operations. Histogen has brought on experienced consultants to advise the team in regulatory, quality and production areas.

Steven J. Mento

Steven J. Mento, Ph.D. has been Histogen's Executive Chairman and Interim President and CEO since November 8, 2021. He joined Histogen’s board of directors in May 2020 following the company’s merger with Conatus Pharmaceuticals.

Know More

Susan A. Knudson

Ms. Knudson, Executive Vice President and Chief Financial Officer, brings over 20 years of public and private experience in finance, corporate strategy, and operations in the life sciences industry to Histogen.

Know More

Gail K. Naughton, Ph.D.

Gail K. Naughton, Ph.D. serves as Histogen's Founder and Scientific Advisor. She previously served as our Chief Scientific Officer & Founder since the Merger in May 2020 to May 31, 2021.

Know More

Martin Latterich, Ph.D.

Dr. Latterich, Histogen's Senior Vice President of Technical Operations, is a biotechnology executive with a strong mix of business and academic experience.

Know More

Michael P. Zimber, Ph.D.

Dr. Michael Zimber, Vice President of Applied Research, has over 25 years of interdisciplinary experience in the biotechnology and pharmaceutical industry.

Know More

Dr. Mark A. Hubka

Dr. Hubka, Executive Director of Clinical Affairs, brings more than 25 years of clinical experience from the fields of orthopedics and sports medicine.

Know More

Thomas Hubka

Thomas Hubka, Senior Director of Business Operations, has spent 12 years with Histogen focusing on business development, finance and operations.

Know More

Steven J. Mento

Know More

David H. Crean

Histogen Lead Independent Director David H. Crean is President & CEO of Coast BioVentures LLC, a life sciences venture investment fund, and a managing partner with Cardiff Advisory, LLC where he leads the firm’s strategic and financial advisory service practice.

Know More

Jonathan Jackson

A few years after completing his degree in Business Management in London, Jonathan Jackson set up his own company to develop commercial real estate in Central Europe.

Know More

Daniel L. Kisner

Dr. Kisner has served on Histogen’s board since May of 2020. He has served as an independent consultant to the pharmaceutical/biotech industry since 2011.

Know More

Brian Satz

Brian M. Satz is an attorney and founder of Satz Law Group LLC in Fairfield, New Jersey. Mr. Satz has extensive experience representing clients in all aspects of corporate and commercial.

Know More

Susan Windham-Bannister, Ph.D.

Susan Windham-Bannister, Ph.D. has been a director at Histogen since March 2021. Dr. Windham-Bannister is an internationally recognized expert in innovation, market access and market optimization strategies.

Know More

Rochelle Fuhrmann

Rochelle Fuhrmann has been a director at Histogen since March 2021. She currently serves as the Vice President Audit and Enterprise Risk Management at Becton Dickinson.

Know More

No current openings

About Histogen

History

Our Mission

Management

Steven J. Mento

Susan A. Knudson

Gail K. Naughton, Ph.D.

Martin Latterich, Ph.D.

Michael P. Zimber, Ph.D.

Dr. Mark A. Hubka

Thomas Hubka

Board of Directors

Steven J. Mento

David H. Crean

Jonathan Jackson

Daniel L. Kisner

Brian Satz

Susan Windham-Bannister, Ph.D.

Rochelle Fuhrmann

Careers